Positive results from trials of Pradaxa in AF-Boehringer

With data now available from all four trials of drugs for Stroke prevention in Atrial Fibrillation, Pradaxa (dabigatran etexilate) 150mg bid, from Boehringer, continues to be the only one of which showed a significant reduction of both ischaemic and haemorrhagic strokes compared to warfarin in its pivotal trial RE-LY.

Pradaxa demonstrated a 25% reduction in the risk of ischaemic strokes and a 74% reduction in the risk of haemorrhagic strokes versus warfarin. Furthermore, rates of total bleeds and life threatening bleeds were significantly reduced versus warfarin. It also showed non-inferior efficacy versus warfarin for reducing risk of stroke with significantly reduced rates of total and major bleeds. Data was presented at the American Heart Association�s Scientific Sessions.